After a median follow-up of 63 months ( IQR 50-82 ) , 5-year biochemical disease-free survival was significantly better among patients receiving long-term androgen deprivation than among those receiving short-term treatment ( 90 % [ 95 % CI 87-92 ] vs 81 % [ 78-85 ] ; hazard ratio [ HR ] 188 [ 95 % CI 112-315 ] ; p = 001 ) .